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Cyclic AMP-rnediat~ phospho~la~on of calcium channel subunits was studied in vitro and in vivo in preparations from dog heart. Calcium 
channels in native cardiac membranes were phosphorylated by CAMP-dependent protein kinase (PKA) solubilized with digitonin and subsequently 
immunoprecipitated using a polyclonal antibody generated against the deduced carboxy-terminal sequence of the cardiac /I subunit. A 62 kDa 
protein was identified as the major PKA-substrate in the immunoprecipitates. In the intact myocardium, this putative p subunit was found to be 
phosphorylated in response to CAMP elevating agents. In contrast, no phosphorylation of a protein with an electrophoretic mobility similar to 
the a, subunit was detected, although 1,4diiydropyridine receptor sites were recovered in the immunoprecipitates. Thus, we suggest that 
IX&mediated phospho~lation of the b subunit is the major mechanism for @-adrenergic regulation of cardiac L-type calcium channel activity. 
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1. I~RODU~ON 
The dihydropyridine-sensitive L-type calcium chan- 
nel is causally involved in the modulation of cardiac 
contractility. Stimulation of /I-adrenoceptors leads to 
an enhanced calcium influx, which is believed to be the 
result of protein phospho~iation catalyzed by a CAMP- 
dependent protein kinase [l-3]. However, the target 
proteins which may be phosphoryiated are still un- 
known. Besides the channel itself [4] distinct regulatory 
proteins may serve as substrates for phosphoryiation 
[5,6]. If the channel is the target, phosphoryiation sites 
may reside in one of four subunits termed a,, az, p, and 
S, which form the oiigomeric cardiac calcium channel 
complex [7-l 21. 
with the amino acid sequence deduced from the cloned 
cardiac cxl subunit 18 lacking serine-687 which is the 
major phosphoryiation site in the skeletal muscle CI, 
subunit [19]. Recently, it has been reported by Yoshida 
[20] that carboxy-terminal sites within the full-length 
cardiac czl subunit undergo phosphoryiation by PKA 
and may transduce the CAMP effect on channel open- 
ing. However, these results have not been confirmed by 
other laboratories [21]. 
For the skeletal muscle calcium channel, it seems to 
be clear that the rzl subunit is the relevant channel com- 
ponent involved in/%adrenergic signal transduction. Ai- 
though both the a, and the /? subunits of this channel 
are substrates for PKA in vitro [13,14], the ~1, subunit 
is favoured as the primary target of PKA in intact mus- 
cle. The phosphoryiation of this protein alone leads to 
increased calcium channel activity in skeletal muscle 
[15,16]. 
There is increasing evidence that the B subunit deter- 
mines some basic properties of the calcium channel 01, 
subunit [I 1,12,21-231. Recently, cardiacg subunits have 
been predicted by cDNA cloning. The deduced amino 
acid sequences how potential PKA phosphoryiation 
sites [i 1,12,24], but whether phosphoryiation occurs in 
vivo remains to be elucidated. 
This study reports on CAMP mediated phosphoryla- 
tion of the j subunit in intact dog myocardium. Im- 
munopr~ipitation with a specific anti-~ptide antibody 
was used to quantify the phosphoryiation. The results 
suggest that the canine cardiac fi subunit is a 62 kDa 
protein which is phosphoryiated by PKA in vitro as well 
as in vivo. 
In cardiac muscle however, the target of PKA is still 
unclear. Biochemical studies using purified calcium 
channels gave no indication for a CAMP-dependent 
phosphoryiation of the a, subunit [8,9,17]. This is in line 
2. MATERIALS AND METHODS 
2.1. Materials 
*Corresponding author. Fax: (49) (30) 9406-3382. 
Abbreviatj~ns: DHP, dihydrop~dine; PKA, cAMP~e~ndent pro- 
tein kinase; PN200-110, isopropyl 4-(2,1,3-benzoxadiazol-4-yl)-1,4- 
dihydro-2,6-dimethyl-5-(methoxy-carbonyl)p~idine-3-carboxyla~. 
Drugs and chemicals were obtained from following sources: ad- 
juvant peptide, digitonin, w-aminohexyl-agarose, I-methyl-3-isobu- 
tylxanthine, Sigma; (+)-[3H]PN20CW10 (spec. act. 85 Wmmol), 
[y-‘?JATP (spec. act. 3000 C~~oi), Amersham; ~9,21-3H~J~an- 
odine (60 Ci/mmol), S-methyl-~3H~nit~ndipine (sp c. act. 79 Wmmol) 
New England Nuclear; protein A-Sepharose CL_4B, Pharmacia; he- 
mocyanin, keyhole limpet (lot 001738), Calbiochem; 2-iminothiolane 
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hydrochloride, Fluka; bovine serum albumin (fraction V), Serva; rab- 
bit IgG, Jackson, ImmunoResearch Labs.; pentobarbital, Abbott 
Labs, North Chicago; nL-isoprenaline Kodak, UK, reserpine, 
Arzneimittelwerk Dresden. Soluble digitonin was prepared as in [9]. 
The catalytic subunit of PKA was prepared from bovine heart accord- 
ing to [25]. 
2.2. Synthetic peptide 
The peptide P-339 (EWNRDVYIRQ) corresponding to the car- 
boxy-terminal residues 597606 of CaB2a or residues 623-632 of 
CaB2b according to the nomenclature given in [11] was synthesized 
by the solid-phase method [26] and purified by reversed-phase HPLC 
on a Vydac 214 TP 1010 (10 pm particle sire) column. To optimize 
coupling to SH-activated carriers the peptide was synthesized with an 
N-terminal chloroacetyl-glycine xtension [27]. The identity of the 
purified peptides was verified by amino acid analysis. 
2.3. Preparation of antibodies 
Keyhole limpet hemocyanin (KLH) was activated with a IO-fold 
molar excess of 2-iminothiolane hydrochloride (Traut reagent) for 20 
min at room temperature. Activated KLH was rapidly separated from 
the reagent by chromatography on a Sephadex G-25 column. The 
purified mono-chloroacetyl-glycine p ptide P-339 was allowed to cou- 
ple to activated KLH for 3 h at room temperature. The molar pep- 
tide:KLH ratio was 41. Aliquots of the KLH-peptide was stored 
frozen at -20°C until use. Initial immunization was performed using 
a mixture of KLH-peptide with rabbit antiserum (1 ml) raised against 
KLH. After l-week the New Zealand white rabbits were immunized 
with KLH-peptide (calculated as 200 pg coupled peptide) and 100 pug 
adjuvant peptide at multiple intradermal sites. Booster injections were 
performed in the same manner when the titer of antibodies dropped. 
Antisera were collected after the second injection and tested for their 
ability to precipitate [3111PN200-1 10 labeled cardiac calcium channels. 
The epitope recognized by pAb-339 was determined by indirect im- 
munophosphatase staining of nitrocellulose transfers of dog heart 
sarcolemmal membranes as described [28]. To purify the antibodies, 
the monochloroacetyl-glycine p ptide P-339 was immobilized to acti- 
vated w-aminohexyl-agarose in the same manner as described for the 
coupling of the peptide to activated KLH. The antibodies pAb-339 
were purified on P-339 resin columns as described [28]. 
2.4. Treatment of dogs and tissue sampling 
Experiments were performed in accordance with internationally 
accepted principles concerning the care and use of laboratory animals. 
Mongrel dogs of either sex (15-20 kg) were anaesthetized by pentobar- 
bital (35 mg/kg body weight) and artificially respirated with a mixture 
of nitrous oxide and oxygen (3:1.2). Left thoracotomy was performed. 
For maximal /?-adrenergic stimulation of the heart a group of animals 
was pretreated with the phosphodiesterase inhibitor 1-methyl-3-isobu- 
tylxanthine (IBMX; 2 mg/kg of body weight, i.v.) for 5 min. Then 
isoprenaline (10 &kg of body weight) was introduced into the cavity 
of the left ventricle of the heart. Tissue samples of the left ventricular 
wall were rapidly frozen in situ at the maximum response in contractile 
force development (20 s after drug application) by a Wollenberger 
clamp precooled in liquid nitrogen. Another group of animals was 
pretreated with reserpine to deplete hearts of catecholamines as de- 
scribed in [29] for two days before the acute experiment was per- 
formed. A third group of open-chest, artiticially respirated ogs was 
left untreated as controls. Tissue samples from the left ventricle were 
removed as described above. Freeze-clamped heart samples were 
stored under liquid nitrogen. 
2.5. Phosphorylation and labeling of receptors in cardiac membranes 
Fractions of total cardiac membranes were prepared from frozen 
tissue samples as described in [30]. Cardiac membranes (3 mg of 
protein) were phosphorylated, if not stated otherwise, in a final vol- 
ume of 1.5 ml with 0.63 PM catalytic subunit of PKA and 10 PM 
[r-“P]ATP (2-3 nCi/pmol) for 6 min at 30°C in a medium containing 
40 mM HEPESiTris-buffer, pH 7.4, 15 mM MgCl,, 0.1% digitonin, 
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1 mM EGTA, 5 mM EDTA, 12.5 mM NaF and 25 mM Pi. The 
phosphorylation reaction was started by addition of [Y-~*P]ATP and 
terminated by addition of 4 ml ice-cold buffer A consisting of 20 mM 
Tris-HCl buffer, pH 7.4, 10 mM EDTA. Phosphorylated membranes 
were spun down at 100,000 x g at 4’C, washed with buffer A and 
pelleted again. The phosphorylated membranes were solubilized in 1% 
digitonin with a 1O:l (w/w) detergent to protein ratio in 50 mM NaCl, 
20 mM Tris-HCl buffer, pH 7.4, and protease inhibitors (0.1 mM 
phenylmethylsulfonyl fluoride, 1 mM iodoacetamide, 0.1 mM ben- 
zamidine, 1 PM pepstatin A) at 0°C for 40 min. Insoluble material was 
removed by centrifugation at 100,000 x g for 30 min. The DHP recep- 
tor of the canine cardiac calcium channel was prelabeled with 10 nM 
(+)-[3H]PN20(rl10 as described [9]. The ryanodine receptor of the 
calcium release channel was prelabeled with 5 nM of [3H]ryanodine 
according to [31]. Solubilization of the receptors were performed as 
described for the solubilization of phosphorylated cardiac mem- 
branes. 
2.6. Immunoprecipitation 
Antibody beads were produced by incubation of appropriate 
amounts of pAb-339 rabbit antiserum with preswollen protein A- 
Sepharose (25 mg) in 1 ml PBS (0.9% NaCl, 50 mM NaH,PQ,, pH 7.4) 
for 2 h at room temperature on a rotating wheel. The beads were 
washed subsequently with PBS and buffer B, consisting of 20 mM 
Tris-HCl, pH 7.4, 0.1% BSA, 1.3 mM CaCI,, 0.2% digitonin, and 
protease inhibitors. The antibody beads were mixed with 
phosphorylated, solubilized membrane proteins (derived from 3 mg 
membrane protein) in a final volume of 15 ml of buffer B and the 
incubation continued overnight at 4°C. After precipitation of beads 
by centrifugation (5 s at 13,000 x g) the supematants were removed 
and the beads were washed three times with cold buffer B. SDS sample 
buffer (5% SDS, 50 mM Tris-HCl, pH 7.5, 0.25 M sucrose, 0.075 M 
urea, 60 mM&mercaptoethanol) was then added to the beads and the 
suspension was heated for 2 min at 94’C. Proteins from the supema- 
tant were subjected to SDS-PAGE. 
Immunoprecipitation of the [‘H]PN200-1 lo-labeled receptor was 
performed in the same manner as described for phosphorylated pro- 
teins except lower amounts of both membranes and antibodies were 
employed and 10 PM diltiazem was added to the media. Accordingly, 
3-50~1 pAb-339 rabbit antiserum, 0.5-lO pug affinity purified pAb-339 
IgG or appropriate amounts of preimrmme serum and control rabbit 
IgG were mixed with preswollen protein A-Sepharose (5 mg/assay) 
and incubated with 300 ~1 of solubiiized (+)-[3H]PN200-l lo-labeled 
receptor (20 fmol). Following a binding and washing procedure, the 
radioactivity bound to the beads was measured by liquid scintillation 
counting. The amount of receptor sites remaining in the supematant 
was determined by polyethylene glycol precipitation [9]. All proce- 
dures were performed under yellow light. Immunoprecipitation of the 
[‘Hlryanodine receptor was performed as described for the DHP re- 
ceptor except diltiazem and light protection were omitted. Briefly, 
beads were prepared with 10-50 ~1 of pAb-339 rabbit antiserum and 
mixed with 75 fmol of solubilized ryanodine-receptor from dog heart. 
2.7. SDS-PAGE and autoradiography 
SDS-PAGE was performed according to Laemmli [32] using 5-15% 
gradient polyacrylamide gels. Gels were dried and subjected to autora- 
diography. Incorporated [‘*PIPi was visualized on X-Omat XAR-2 
films (Kodak, USA) and quantified by Fujix BAS 2000 (Japan) equip- 
ment or bands of interest were cut out from dried gels and counted 
by liquid scintillation. 
2.8. Other assays 
Tissue levels of CAMP were analysed in neutralized trichloroacetic 
acid extracts as described in [30]. The activity of CAMP-PK was meas- 
ured as in [33] and is expressed as the ratio between activities assayed 
without and with CAMP (-cAMP/+cAMP). Equilibrium binding 
assays were performed as described in [34]. ATP content was analyzed 
by HPLC according to [35] using a ProPac PA1 column (Dionex, 
USA). 
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3. RESULTS AND DISCUSSION 
A polyclonal antibody was generated by ionizing 
rabbits with a decapeptide, corresponding to the de- 
duced carboxy-terminal amino acid sequence of rabbit 
cardiac calcium channel p subunit [l 11. The antibody, 
termed pAb-339, cross-reacted with canine cardiac anti- 
gens as demonstrated by dose-dependent immunopre- 
cipitation of [JH]PN200-1 lo-labeled calcium channels 
from di~tonin-solubilized og cardiac membranes (Fig. 
1A). Specific immunoprecipitation ranged between 25% 
and 35% of the DHP-ladled receptors present in the 
assay. The same ~unoprecipitation results were ob- 
tained with affinity-purified pAb-339. 
In i~~oblotting experiments no specific interac- 
tion among cardiac antigens derived from different spe- 
ties and pAb-339 was observed, which is probably due 
to specific epitope r~~tion. Obviously, pAb-339 re- 
acted with digitonin confo~ation-de~ndent epitopes 
on the p subunit but not with SDS-solubilized cardiac 
calcium channels. Quite similar behaviour has been re- 
ported for monclonal antib~ies directed against the 
cardiac sarcolemmal Na/Ca exchanger [36]. 
To study whether a component of the calcium chan- 
nel complex serves as substrate for PKA, dog cardiac 
membranes were phosphorylated using [Y-~‘P]ATP and 
the catalytic subunit of PKA. Two major substrates of 
PKA were specifically recovered by subs~uent im- 
munoprecipitation using pAb-339 (Fig. 1 B). The appar- 
ent molecular mass of these phosphoproteins were cal- 
culated to be about 400 kDa and 61.8 + 1.3 kDa 
(mean jt S.D., n = 9). The M, of the latter phosphopro- 
tein corresponds to the molecular mass of rabbit cardiac 
/I subunits deduced from cDNA cloning [l 1,12,24]. 
Since pAb-339 has been raised against the predicted 
sequence of cardiac B sub~t(s), the results strongly 
suggest that the 62 kDa substrate of PKA represents the 
native calcium channel /I subunit protein in canine 
heart. 
The phosphorylation of the 62 kDa /I subunit was 
found to be absolutely dependent on the amount of 
exogenously added PKA (Fig. 2). half-m~mal phos- 








Fig. 1. Immunoprecipitation of labeled dog cardiac calcinm chaunels by the anti-@ subunit antibody pAb-339. (A) The indicated amounts of PAb-339 
(0) or preimmune serum (V) were bound to protein A-Sepharose. The antibody-beads were then incubated with 20 fmoles of [3FBPN200-1 10 labeled 
calcium channels ~lub~~ from dog cardiac rn~br~~ and pelleted. The ~dioa~ti~~ recovered in the precipitate was measured by Iiquid 
scintillation counting. Values are means 51 S.D. for a typical experiment measured in triplicates. (B) Canine cardiac membranes (3 mg of membrane 
protein) were phosphorylated using the catalytic subunit of CAMP-dependent protein kinase and 10 PM [r-“PJATP, soiubilized with 1% of 
digitonin, ~unop~ipitat~ and subjected to SDS-PAGE followed by automdio~aphy for 3 days. Lane 1, 200 ~1 preimmune s rum (Ab-); 
lane 2,200 ~1 pAb-P339 (Ab+). 
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Fig. 2. Phosphorylation of calcium channel j5 subunit by CAMP-de- 
pendent protein kinase. Cardiac membranes from dog were 
phosphorylated for 1 min either in the absence or in the presence of 
increasing concentrations of the catalytic subunit of CAMP-dependent 
protein kinase (0.03-0.63 PM) under standard phosphorylation condi- 
tions. Phosphorylated membranes were solubilized, imnumoprecipi- 
tated with 200 ,ul of pAb-339 and further processed as described in the 
legend to Fig. 1. 
phorylation was observed at a concentration of about 
0.2 ,uM PKA. Time course experiments with saturating 
concentrations of PKA revealed that the j? subunit is 
rapidly phosphorylated. Maximal values of 32Pi ncor- 
poration were reached within 30 s and remained con- 
stant for at least 12 min indicating that no 
dephosphorylation occurred. Furthermore, we have 
confirmed that the concentration of ATP used was suf- 
ficient to saturate the Pi-incorporation into the B sub- 
unit and did not drop below a critical level during the 
phosphorylation reaction. 
In addition to the phosphorylated 62 kDa j? subunit 
a high molecular mass protein of about 400 kDa was 
specifically immunoprecipitated too. Because of simi- 
larities in apparent molecular mass with the sarcoplas- 
mic reticulum ryanodine receptor/calcium release chan- 
nel [37] we tested the possibility whether pAb-339 im- 
munoprecipitates the [3H]ryanodine-labeled receptor 
from solubilized dog heart membranes. No interaction 
between the anti-/? subunit pAb-339 and the ryanodine 
receptor was observed. Therefore, the molecular iden- 
tity of the 400 kDa phosphoprotein and its relation to 
the calcium channel remains to be elucidated. 
To evaluate the phosphorylation of calcium channels 
in intact heart, we employed the technique of back- 
phosphorylation. This is based on the in vitro topping- 
up of phosphorylation of cardiac membrane proteins in 
the presence of an excess of the catalytic subunit of PKA 
and [Y-~‘P]ATP. The induced in vitro 32Pi incorporation 
is inversely related to the in vivo phosphorylation of 
proteins [15,29,30,38,39]. In this report we have com- 
bined the in vitro back-phosphorylation with the im- 
munoprecipitation standardized as described above. 
Cardiac membranes were isolated from dogs either 
acutely stimulated by the B-adrenergic agonist isopre- 
naline or depleted of catecholamines by reserpine as 
well as from untreated controls. Typical autoradiogra- 
phs of immunoprecipitates obtained from in vitro back- 
phosphorylated membranes of the experimental groups 
are shown in Fig. 3. The 32Pi ncorporation into the /I 
Table I 
Consequences of /I-adrenergic stimulation in intact canine myocardium 
Experimental groups CAMP PKA activity “P. incorporation into Ca” 
’ channel /3 subunit 
DHP-labeling of Ca*+ 
(pmol per mg wet weight) (-CAMP/+ CAMP) channel (L, subunit 
(fmohmg membrane protein) (fmol/mg membrane 
protein) 
Reserpine 0.44 + 0.02 (6) 0.12 f 0.01 (7) 8.7 + 0.9 (11) 12.1 
Control 0.49 * 0.03 (3) n.d. 4.6 f 0.5 ( 3) n.d. 
Isoprenaline 2.57 f 0.24 (6); 0.24 f 0.02 (4)* 1.3 f 0.3 ( 5)* 12.9 
The data for CAMP, protein kinase activity ratio, and 32Pi incorporation are given as means+ S.E.M. Numbers in parentheses indicate independent 
experiments with tissue samples derived from at least 3 different animals. Values of DHP-labeling were calculated from B_ taking into 
consideration the recovery of receptors after solubilization and immunoprecipitation, determined to be 38% and 305, respectively. The B,, was 
114 f 17 fmollmg membrane protein (n = 3) and 106 f 20 fmol/mg membrane protein (n = 3) for preparations from the isoprenaline- and 
*P c 0.01 vs. values for control and reserpine. 
reserpine-treated animals, respectively. 
220 
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M, x 1O-3 12 3 
prenaline and the presence of phosphodiesterase inhibi- 
tion caused a rapid and apparently complete phospho- 









Fig. 3. Autoradiograph of back-phosphorylation of the calcium chan- 
nel B-subunit prepared from dog hearts. Cardiac membranes were 
prepared from either control (lane l), reset-pine-treated (lane 2) or 
isoprenaline-treated (lane 3) dogs. The membranes (3 mg of protein 
of each preparation) were in vitro back-phosphorylated using the 
catalytic subunit of the CAMP-dependent protein kinase and 10 PM 
[Y-~~]ATP, solubilized, immunoprecipitated with 200 ~1 of pAb-339 
and autoradiographed as described in the legend to Fig. 1. 
protein was most prominent in preparations from reser- 
pine-treated dogs (Fig. 3, lane 2), reduced in controls 
(lane l), and nearly completely suppressed in samples 
from isoprenaline-treated animals (lane 3). Interest- 
ingly, comparable changes in back-phosphorylation 
were observed for the unidentified 400 kDa 
phosphoprotein (Fig. 3). Another coprecipitating 30 
kDa substrate of PKA, however, was not affected by the 
the j?-adrenergic agonist (Fig. 3). 
Table I summarizes the quantitative data obtained 
for the 32Pi ncorporation into the immunoprecipitated 
calcium channel B subunit. In controls 4.6 + 0.5 fmol 
[32P]phosphate p r mg of membrane protein was incor- 
porated into the j? subunit. Both isoprenaline- and reser- 
pine-treatment caused significant changes in 32Pp From 
the difference in 32Pi incorporation in vitro (isoprenaline 
versus reserpine) a value of 7.4 f 0.3 fmol phosphate 
per mg of membrane protein was calculated for isopre- 
naline-induced B subunit phosphorylation in vivo. In- 
deed, isoprenaline treatment increased CAMP content 
as well as endogenous PKA activity in the same frozen 
tissue samples used for in vitro back-phosphorylation 
(Table I). Obviously, the maximal efficient dose of iso- 
In order to approximate the molar ratio of j? to 01~ 
subunits, j$ subunit phosphorylation data were related 
to the number of DHP binding sites, both recovered by 
immunoprecipitation. Using data from the reserpine 
group, for which a low in vivo phosphorylation is ex- 
pected, the value of the ratio was calculated to be 0.72. 
Concerning the DHP receptor a, subunit the follow- 
ing merits discussion. Although the data presented in 
Fig. 1A clearly demonstrate that DHP binding sites 
were precipitated by pAb-339, no phosphoprotein was 
detected with electrophoretic mobility similar to the 200 
kDa DHP receptor a, subunit (Figs. 1,2,3). This result 
is in close agreement with tindings previously obtained 
by us [9,17] with calcium channels purified from porcine 
heart as well as by Yoshida et al. [20] who used an 
anti-a, antibody to precipitate phosphorylated rabbit 
cardiac calcium channels. But, in contrast to the latter 
authors we did not detect the phosphorylated 250 kDa 
full-length form of the ~1, subunit. The most likely expla- 
nation for this result is the low abundance of the untrun- 
cated 01, form which has been reported not to exceed 
10% of the total amount of DHP receptors [40]. Al- 
though the data do not exclude the possibility that the 
full-length form of the cardiac dir protein serves as a 
substrate of PKA, a physiological role of its phospho- 
rylation is questionable. 
Taken together, our data suggest that the 62 kDa 
protein immunoprecipitated by the anti /l subunit pAb 
339 (i) represents the native calcium channel /3 subunit 
in dog heart and (ii) is a physiological target of PKA. 
These results provide strong evidence for the involve- 
ment of the calcium channel p subunit in j?-adrenergic 
signal transduction in myocardium. 
Acknowledgements: The authors thank Hanna Sydow, Irmgard 
Kiittner and Ingrid Ameln for their excellent experimental work, Dr. 
Margit Pissarek for her support in HPLC analysis of ATP and Drs. 
Enno Hartmann and Tom Rapoport for their helpful advice in design- 
ing peptide antibodies. We also wish to thank Dr. Franz Hofmann for 
stimulating discussions and Nicholas Freestone for critical reading the 
manuscript. The work was partly supported by Deutsche Forschungs- 
gemeinschaft, Sonderforschungs-bereich 246. 
REFERENCES 
[l] Reuter, H. (1983) Nature 301, 569-574. 
[2] Tsien, R.W., Bean, BP, Hess, P., Lansman, J.B., Nilius, B. and 
Nowycky, MC. (1986) J. Mol. Cell. Cardiol. 18, 691-710. 
[3] HartzelI, H.C., Mery, P.F., Fischmeister, R. and Szabo, G. (1991) 
Nature 351, 573-576. 
[4] Trautwein, W. and Hescheler, J. (1990) Annu. Rev. Physiol. 52, 
257. 
[5] Presti, C.F., Jones, L.R. and Lindeman, J.P. (1985) J. Biol. Chem. 
260, 3860-3867. 
[6] Palmer, C.J., Scott, B.T. and Jones, L.R. (1991) J. Biol. Chem. 
266, 1112611130. 
221 
Volume 335, number 2 FEBSLETTERS December 1993 
[7] Schneider, T. and Hofmann, F. (1988) Eur. J. Biochem. 174, 
127-135. 
[8] Chang, C.F. and Hosey, M.M. (1988) J. Biol. Chem. 263, 18929- 
18937. 
[9] Haase, H., Striessnig, J., Holtzhauer, M., Vetter, R. and Gloss- 
mann H. (1991) Eur. J. Pharmacol. 207, 51-59. 
[lo] Tokumaru, H., Anzai, K., Abe, T. and Kirino, Y. (1992) Eur. J. 
Phannacol. 227, 363-370. 
[l l] Hullin, R., Singer-Lahat, D., Freichel, M., Biel, M., Dascal, M., 
Hofmann, F. and Flockerzi, V. (1992) EMBO J. 11, 885-890. 
[12] Perez-Reyes, E., Castellano, A., Kim, H.S., Bertrand, P., 
Baggstrom, E., Lacerda, A.E., Wei, X. and Bimbaumer, L. (1992) 
J. Biol. Chem. 267, 1792-1797. 
[13] Imagawa, T., Leung, A.T. and Campbell, A.T. (1987) J. Biol. 
Chem. 262, 8333-8339. 
[14] Nastainczyk, W., Riihrkasten, A., Sieber, M., Rudolph, C., 
Schachtele, C., Marme, D. and Hofmann, F. (1987) Eur. J. Bio- 
them. 169, 137-142. 
[15] Mundina-Weilenmann, C., Chang, C.F., Gutierrez, L.M. and 
Hosey, M.M. (1991) J. Biol. Chem. 266, 40674073. 
[16] Chang, C.F., Gutierrez, L.M., Mundina-Weilemann, C. and 
Hosey, M.M. (1991) J. Biol. Chem. 266, 16395-16400. 
[17] Haase, H., Vetter, R., Striessnig, J., Hohzhauer, M. and Gloss- 
mann, H. (1992) in: Tada M. (Ed.) Molecular Biology of the 
Myocardium, Japan Scientific Societies Press, Tokyo and CRC 
Press, Boca Raton/Ann Arbor/London/Tokyo, pp. 169-180. 
[18] Mikami, A., Imoto, K., Tanabe, T., Niidome, T., Mori, Y., Take- 
shima, H., Narumiya, S. and Numa, S. (1989) Nature 340,230- 
233. 
[19] Riihrkasten, A., Meyer, H.E., Nastainczyk, W., Sieber, M. and 
Hofmann, F. (1988) J. Biol. Chem. 263, 15325-15329. 
[20] Yoshida, A., Takahashi, M., Nishimura, S., Takeshima, H. and 
Kokubun, S. (1992) FEBS Lett. 309, 343-349. 
[21] Hofmann, F., Biel, M. and Flockerzi, V. (1994) Annu. Rev. 
Neurosci. 17, in press. 
[22] Nishimura, S., Takeshima, H., Hofmann, F., Flockerzi, V. and 
Imoto, K. (1993) FEBS Lett. 324, 283-286. 
[23] Klockner, U., Itagaki, K., Bodi, I. and Schwartz, A. (1992) 
Ptliigers Arch. Eur. J. Physiol. 420,413415. 
[24] Collin, T., Wang, J.J., Nargeot, J. and Schwartz, A. (1993) Circ. 
Res. 72, 1337-1344. 
[25] Peters, K.A., Demaille, J.G. and Fisher, E.H. (1977) Biochemis- 
try 16, 5691-5697. 
[26] Schnorrenberg, G. and Gerhardt, H. (1989) Tetrahedon 45, 
7759- 7762. 
[27] Lindner, W. and Robey, F.A. (1987) Int. J Peptide Protein Res. 
30, 794800. 
[28] Haase, H., Karczewski, P. (1994) Biol. Chem. Hoppe-Seylers (in 
press). 
[29] Karczewski, P., Bartel, S., Haase, H. and Krause, E.G. (1987) 
Biomed. B&him. Acta 46,433-439. 
[30] Karczewski, P., Bartel, S. and Krause, E.G. (1990) B&hem. J. 
266, 115-122. 
[31] Sakamoto, J. and Campbell, K.P. (1991) J. Biol. Chem. 266, 
1891418919. 
[32] Laemmli U.K. (1970) Nature 227, 68@685. 
[33] Bartel, S., Krause, E.G. and Wollenberger, A. (1985) Biomed. 
Biochim. Acta 44, 1303-1313. 
[34] Haase, H., Vetter, R., Will, H. and Will-Shahab, L. (1986) 
Biomed. Biochim. Acta 45, S223S226. 
[35] Herpich, B. and Krauss, G.J. (1992) J. High Resolution Chrom. 
14, 4142. 
[36] Vemuri, R., Haberland, M.E., Fong, D. and Philipson, K.D. 
(1990) J. Membrane Biol. 118, 279-283. 
[37] Yoshida, A., Takahashi, M., Imagawa, T., Shigekawa, M., 
Takisawa, H. and Nakamura T. (1992) J. Biochem. 111,186190. 
[38] Forn, J. and Greengard, P. (1978) Proc. Natl. Acad. Sci. USA 75, 
5195-5199. 
[39] Lai, Y., Seagar, M., Takahashi, M. and Catterall, W.A. (1990) 
J. Biol. Chem. 265, 20839-20848. 
[40] De Jongh, KS., Warner, C., Colvin, A.A. and Catterall, W.A. 
(1991) Proc. Natl. Acad. Sci. USA 88, 10778-10782. 
222 
